期刊文献+

原发性骨髓纤维化治疗进展 被引量:3

原文传递
导出
摘要 原发性骨髓纤维化(PMF)是经典的BCR—ABL1阴性骨髓增殖性肿瘤(MPNs)中最严重的一个亚型,属于造血干细胞异常克隆性疾病,PMF的临床表现为异质性,大多数患者出现贫血、脾脏肿大或者发热、乏力、盗汗、消瘦、骨痛等全身症状,随着疾病进展出现髓外造血,最终发展为骨髓衰竭或转化为急性髓系白血病而死亡,PMF在MPNs中预后最差,中位生存期约5年。
作者 左学兰 张岘
出处 《临床内科杂志》 CAS 2016年第3期158-161,共4页 Journal of Clinical Internal Medicine
  • 相关文献

参考文献12

  • 1Rampal R, Mascarenbas J. Pathogenesis and management of acute mye- loid leukemia that has evolved from a myeloproliferative neoplasm [ J 1. Curr Opin Hematol,2014,21 (2) :65-71.
  • 2Ortmann CA, Kent DG, Nangalia J, et al. Effect of mutation order on myeloproliferative neoplasms[J]. N Engl J Med,2015,372(7) :601-612.
  • 3Tefferi A, Lasho TL, Mesa RA, et al. Lenalidomide therapy in del (5) (q31)-associated myelofibrosis : cytogenetic and JAK2V617F molecular remissions[ J]. Leukemia,2007,21 ( 8 ) : 1827-1828.
  • 4Gupta V, Malone AK, Hari PN, et al. Reduced-intensity hematopoietic cell transplantation for patients with primary myelofibrosis: a cohort analysis from the center for international blood and marrow transplant research[ J]. Biol Blood Marrow Transplant,2014,20( 1 ) :89-97.
  • 5Komrokji RS, Seymour JF, Roberts AW, et al. Resnhs of a phase 2 study of pacritinib( SB1518 ), a JAK2/JAK2 (V617F) inhibitor, in patients with myelofibrosis[ J ]. Blood ,2015,125 ( 17 ) :2649-2655.
  • 6Pardanani A, Laborde RR, Lasho TL, et al. Safety and efficacy of CYT387, a JAK1 and JAK2 inhibitor, in myelofibrosis [ J ]. Leukemia, 2013,27(6) :1322-1327.
  • 7Masearenhas J, Lu M, Li T, et al. A phase I study of panobinostat (LBH589) in patients with primary myelofibrosis (PMF) and post- polycythaemia vera/essential thrnmbocythaemia myelofibrosis( post-PV/ ET MF) [ J]. Br J Haematn1,2013,161 ( 1 ) :68-75.
  • 8Quint6s-Cardama A,Tong W, Kantarjian H, et al. A phase II study of 5-azacitidine for patients with primary and post-essential thrombythemia/ polycythemia vera myeLofibmss [ J ]. Leukemia ,200$ ,22 ( 5 ) :965-970.
  • 9Weigert O, Lane AA, Bird L, et al. Genetic resistance to JAK2 enzymat- ic inhibitors is overcome by HSP90 inhibition [ J ]. J Exp Med, 2012, 209 (2) :259-273.
  • 10Papadantonakis N, Matsuura S, Ravid K. Megakaryocyte pathology and bone marrow fibrosis : the lysyl oxidase connection [ J ]. Blood,2012,120 (9) :1774-1781.

同被引文献16

引证文献3

二级引证文献3

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部